Research programme: small molecule therapeutics - Centogene/Evotec
Latest Information Update: 11 Jun 2024
At a glance
- Originator Centogene; Evotec SE
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Gaucher's disease
Most Recent Events
- 14 May 2024 Preclinical trials in Gaucher's disease in Germany (unspecified route)
- 22 Jan 2024 Research development is ongoing for Gaucher's-disease in Germany (Evotec pipeline, January 2024)
- 28 Sep 2022 No recent reports of development identified for research development in Gaucher's-disease in Germany